Typical time-traces of a subject walking at ~1.39 m s^-1 (5 km h^-1) on a -9° slope (left column), on the level (middle column) and on a +9° slope (right column... by Arthur H. Dewolf (4537918)

Table_2_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

“…Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. …”

Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

“…Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. …”

Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

“…Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. …”

Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

“…Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. …”

Image_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.PDF by Emilie Faivre (5507582)

“…Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. …”

Effect of SNX5 S226 phosphorylation on macropinocytosis. by Nao Itai (5954666)

Subjects:

Patterns of satisfaction level of communities along a distance gradient (from the closest community to the furthest community away from the mining operation site). by Mothusi Boihang (13149705)

The effects of CGA on NLRP3 inflammasome and the Nrf2 pathway in HK-2 cells. by Liping Bao (2936715)

related to Fig 3. (A) Live eggs induce AIM2 pyroptosome formation. Microscopy of AIM2-citrine macrophages stimulated with live eggs for 48 h. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

The effects of CGA on NLRP3 inflammasome and the Nrf2 pathway in high-fat diet (HFD)/ streptozotocin (STZ) -induced diabetic kidneys. by Liping Bao (2936715)

LM11A-31 reverses dystrophy of cholinergic neurites that occurs with aging in APP^L/S mice. by Danielle A. Simmons (621167)

“…<p>Quantitative analysis of the effect of aging showed that 13–14 month old vehicle-treated APP^L/S (APP) mice had ChAT neurites in basal forebrain with decreased (<b><i>A</i></b>) length and (<b><i>B</i></b>) area and had dystrophic neurite clusters in cortex that occupied more area (<b><i>C</i></b>) and were larger (<b><i>D</i></b>) compared to the 9–11 month old APP Veh mice. …”

<i>Myotis rufoniger</i> genome sequence and analyses: <i>M</i>. <i>rufoniger’s</i> genomic feature and the decreasing effective population size of <i>Myotis</i> bats by Youngjune Bhak (3511349)

“…<div><p><i>Myotis rufoniger</i> is a vesper bat in the genus <i>Myotis</i>. Here we report the whole genome sequence and analyses of the <i>M</i>. …”

The mean by treatment group daily viral shedding as measured by polymerase chain reaction of bovine respiratory syncytial virus from nasal swabs. by Paul Walsh (662015)

LPC-DHA inhibits Srebp activity and de novo lipogenesis and Mfsd2a is regulated by Srebp. by Jia Pei Chan (5593388)

“…Scd1 expression in NSC^WT cells decreased with LPC-DHA treatment, but to a lesser extent in NSC^KO cells. β-actin served as a loading control. …”

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: